Meeting
2023 ASCO Annual Meeting
Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.
Authors
Helen Ajufo
Memorial Sloan Kettering Cancer Center, New York, NY
Helen Ajufo , Jan Philipp Bewersdorf , Claire Harrison , Francesca Palandri , John Mascarenhas , Jeanne M. Palmer , Aaron Thomas Gerds , Jean-Jacques Kiladjian , Andriy Derkach , Raajit Rampal , Sarah Buckley , Karisse Roman-Torres
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myelodysplastic Syndromes (MDS)
Clinical Trial Registration Number
NCT02055781
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7018)
DOI
10.1200/JCO.2023.41.16_suppl.7018
Abstract #
7018
Poster Bd #
148
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.
First Author: Pankit Vachhani
Poster
2023 ASCO Quality Care Symposium
Ruxolitinib for the prophylaxis of graft-versus-host disease in patients with myelofibrosis receiving hematopoietic stem cell transplantation.
First Author: Tina Yi Jin Hsieh
Poster
2023 ASCO Annual Meeting
Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study.
First Author: Jie Jin
Poster
2023 ASCO Annual Meeting
Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias.
First Author: Prithviraj Bose